EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

In vitro activity of aztreonam/avibactam and comparators against Enterobacterales isolates from patients with hospital-acquired pneumonia, ventilator-associated pneumonia, and complicated intra-abdominal infections (ATLAS, 2021–2022)

In-vitro-Aktivität von Aztreonam/Avibactam und Vergleichspräparaten gegen Enterobacterales-Isolate von Patient:innen mit HAP, VAP und komplizierten intraabdominellen Infektionen (ATLAS, 2021–2022)

Qiwen Yang iD, Felipe Francisco Tuon iD, Sweta Shah, Shweta Kamat, Naglaa Mohamed, Gregory G Stone, Katherine K Perez iD, Rafael Cantón iD

Journal of Antimicrobial Chemotherapy · 03.06.2026 · 81 (7)

DOI: 10.1093/jac/dkag198 ↗

Auf einen Blick

Aztreonam/Avibactam zeigte gegen Enterobacterales-Isolate eine hohe In-vitro-Aktivität, auch bei MBL-positiven Stämmen. Bei E. coli mit PBP3-Insertionen und plasmidvermittelten AmpC war die Aktivität deutlich geringer.

Fragestellung

Wie aktiv ist Aztreonam/Avibactam in vitro gegen Enterobacterales aus HAP, VAP und cIAI im Vergleich zu anderen Substanzen, besonders bei MBL-positiven Isolaten?

Methode

14 564 Enterobacterales-Isolate aus dem globalen ATLAS-Programm 2021–22 wurden per Bouillon-Mikrodilution getestet; CRE wurden molekular charakterisiert, MBL-positive Isolate zusätzlich analysiert.

Ergebnisse

Aztreonam/Avibactam war bei allen Enterobacterales zu 99,5 % empfindlich (MIC90 0,25 mg/L), bei MDR zu 98,9 %, bei ESBL zu 99,0 % und bei CRE zu 96,4 %. Unter 577 MBL-positiven Isolaten lag die Empfindlichkeit bei 95,1 %; Cefiderocol 50,3 %, Colistin 73,8 %, Tigecyclin 95,0 %.

Schlussfolgerung der Autor:innen

Aztreonam/Avibactam zeigte eine starke und konsistente In-vitro-Aktivität gegen Enterobacterales aus schweren Krankenhausinfektionen, einschließlich MBL-produzierender CRE.

Kernaussagen

  • 99,5 % empfindlich bei allen Enterobacterales; MIC90 0,25 mg/L
  • Bei 577 MBL-positiven Isolaten 95,1 % empfindlich
  • E. coli mit PBP3-Insertionen und AmpC: 31,4 % empfindlich

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 10.06.2026. Verfasst von Qiwen Yang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Laboratory, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy o…. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Azabicyclo Compounds, Aztreonam, Enterobacteriaceae. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pfizer Inc..

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP) and complicated intra-abdominal infections (cIAIs) caused by carbapenem-resistant Enterobacterales (CRE) are associated with high mortality. Metallo-β-lactamase (MBL)-producing strains represent therapeutic challenge compromising β-lactams and limiting treatment options. Aztreonam/avibactam is a novel combination designed to overcome MBL-mediated resistance.

Objectives

To evaluate in vitro activity of aztreonam/avibactam and comparators against Enterobacterales from patients with HAP, VAP or cIAI collected globally (Africa/Middle East, Asia-Pacific, Europe and Latin America) during 2021–22 ATLAS surveillance program focusing on MBL-positive strains.

Methods

14 564 Enterobacterales isolates were tested by broth microdilution per CLSI guidelines. CRE isolates underwent molecular characterization and MBL-positive isolates underwent additional molecular and susceptibility analysis, including cefiderocol. MBL-positive Escherichia coli isolates were screened for PBP3 mutations by whole-genome sequencing. MICs were interpreted using EUCAST breakpoints as appropriate.

Results

Aztreonam/avibactam was 99.5% susceptible (MIC ≤4 mg/L) for all Enterobacterales (MIC90 0.25 mg/L) and maintained high susceptibility against MDR (98.9%), ESBL (99.0%) and CRE (96.4%). Among 577 MBL-positive isolates (88% NDM), aztreonam/avibactam was 95.1% susceptible, compared with cefiderocol (50.3%), colistin (73.8%) and tigecycline (95.0%). Activity was consistent across regions and carbapenemase genotypes, including co-producers of multiple β-lactamases. However, E. coli isolates harbouring PBP3 insertions (YRIK/YRIN) and plasmid-mediated AmpC β-lactamases (n = 35) were 31.4% susceptible (MIC ≤4 mg/L).

Conclusions

Aztreonam/avibactam demonstrated potent and consistent in vitro activity against Enterobacterales causing serious hospital infections, including MBL-producing CRE. These findings underscore aztreonam/avibactam’s therapeutic potential and the need for rapid diagnostics and global surveillance to guide regional stewardship and treatment strategies for MDR infections.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Bacterial AgentsAzabicyclo CompoundsAztreonamEnterobacteriaceaeHealthcare-Associated PneumoniaIntraabdominal InfectionsPneumonia, Ventilator-AssociatedHumansbeta-LactamasesCarbapenem-Resistant EnterobacteriaceaeCefiderocolEnterobacteriaceae InfectionsMicrobial Sensitivity Tests

Substanzen

Anti-Bacterial AgentsavibactamAzabicyclo CompoundsAztreonambeta-LactamasesCefiderocol

Autor:innen und Institutionen

  • Department of Clinical Laboratory, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Laboratory of Emerging Infectious Diseases, Pontifícia Universidade Católica do Paraná, Curitiba, Paraná, Brazil.
  • Department of Microbiology, Kokilaben Dhirubhai Ambani Hospital and Research Institute, Mumbai, India.
  • Pfizer Products India Private Limited, Mumbai, India.
  • Pfizer Inc., NewYork, NY, USA.
  • Pfizer Inc., Groton, CT, USA.

ORCID-Profile: Qiwen Yang, Felipe Francisco Tuon, Katherine K Perez, Rafael Cantón

Förderung

  • Pfizer Inc.

Zitieren

APA

Yang, Q., Tuon, F. F., Shah, S., Kamat, S., Mohamed, N., Stone, G. G., Perez, K. K., & Cantón, R. (2026). In vitro activity of aztreonam/avibactam and comparators against Enterobacterales isolates from patients with hospital-acquired pneumonia, ventilator-associated pneumonia, and complicated intra-abdominal infections (ATLAS, 2021–2022). Journal of Antimicrobial Chemotherapy, 81(7). https://doi.org/10.1093/jac/dkag198

Vancouver

Yang Q, Tuon FF, Shah S, Kamat S, Mohamed N, Stone GG, et al. In vitro activity of aztreonam/avibactam and comparators against Enterobacterales isolates from patients with hospital-acquired pneumonia, ventilator-associated pneumonia, and complicated intra-abdominal infections (ATLAS, 2021–2022). Journal of Antimicrobial Chemotherapy. 2026;81(7). doi:10.1093/jac/dkag198

BibTeX
@article{Yang2026,
  author = {Yang, Qiwen and Tuon, Felipe Francisco and Shah, Sweta and Kamat, Shweta and Mohamed, Naglaa and Stone, Gregory G and Perez, Katherine K and Cantón, Rafael},
  title = {In vitro activity of aztreonam/avibactam and comparators against Enterobacterales isolates from patients with hospital-acquired pneumonia, ventilator-associated pneumonia, and complicated intra-abdominal infections (ATLAS, 2021–2022)},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2026},
  volume = {81},
  number = {7},
  doi = {10.1093/jac/dkag198}
}
Kostenlos starten →